Steven St. Peter, M.D.
President and Chief Executive Officer
Steven St. Peter, M.D. is one of our founders and has served as our President and Chief Executive Officer since September 2012. He has been a member of our Board of Directors since December 2010 and served as the Chairman of our Board of Directors from December 2010 to September 2012. Dr. St. Peter was a Managing Director of MPM Asset Management LLC from January 2004 to May 2012, where he focused his investments on both venture and buyout transactions across the pharmaceuticals and medical technology industries. He has previous investment experience from Apax Partners and The Carlyle Group, two private equity firms. Dr. St. Peter was previously an Assistant Clinical Professor of medicine at Columbia University. He received his M.D. from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. Prior to his medical training, he was an investment banker at Merrill Lynch. Dr. St. Peter also holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas. Dr. St. Peter previously served as a director of PharmAthene, Inc., a publicly-traded biodefense company, from August 2007 through May 2017 as a member of its governance and nominating committee. Dr. St. Peter has also served as a member of the Board of Directors of the Kansas City Area Life Sciences Institute since March 2014 and as a member of the Board of Directors of the Greater Kansas City Foundation since November 2015. Dr. St. Peter’s previous board experience includes MPM Acquisition Corp., Proteon Therapeutics, Inc., Rhythm Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc.
Craig Tooman, MBA
Chief Financial Officer
Craig Tooman, MBA, has served as our Chief Financial Officer since November 2013 and our Treasurer since January 2014. He was a member of our Board of Directors from April 2012 to November 2013, before accepting the CFO role. Mr. Tooman previously served as the Chief Executive Officer of Avanzar Medical, Inc., a privately-held company focused on commercial oncology opportunities, from February 2012 until November 2014. Mr. Tooman was also the founder and principal of Stockbourne LLC, a firm that provides strategic business and financial advisory services, a position he held from January 2011 to November 2013. From July 2010 to January 2011, Mr. Tooman was the Senior Vice President of Finance and Chief Financial Officer of Ikaria Inc., a biotherapeutics company. From January 2005 to July 2010, Mr. Tooman was the Executive Vice President of Finance and Chief Financial Officer at Enzon Pharmaceuticals, a biopharmaceutical company. Prior to that, Mr. Tooman was the Senior Vice President of Strategic Planning and Corporate Communications at ILEX Oncology, Inc. and the Vice President of Investor Relations at Pharmacia Corporation. Mr. Tooman previously served on the Board of Directors of Insite Vision Incorporated, a publicly-traded ophthalmological company, from September 2011 to November 2015. Mr. Tooman also served on the Board of Directors and as chair of the audit committee of Xanodyne Pharmaceuticals Inc., a privately-held specialty pharmaceutical company, from October 2007 until it was acquired in June 2013 upon the sale of its commercial assets. He has a B.A. in Economics from Kalamazoo College and M.B.A. in Finance from the University of Chicago.
Chief Operating Officer
Brent Standridge has served as our Chief Operating Officer since July 2016. Prior to accepting the Chief Operating Officer role, Mr. Standridge served as a consultant to the Company from January 2016 through June 2016. Previously, Mr. Standridge formed a consulting business, providing commercial and operations-related services to animal health companies, including from July 2010 to May 2014, serving as a commercial consultant for Putney, Inc., a privately-held pet pharmaceutical company. Prior to that, he worked for Fort Dodge Animal Health, a global manufacturer of animal health products and division of Wyeth, from 1982 until February 2010, where he held numerous sales and marketing positions including Senior Vice President of Sales and Marketing, North America from 1999 until February 2010. During his career with Fort Dodge, Mr. Standridge was responsible for developing and building species-specific sales forces to maximize company sales, fully leverage marketing initiatives and provide optimal customer service as well as being instrumental in the acquisition and integration of several companies and business units. Mr. Standridge earned a Bachelor of Science in Animal Science and Agricultural Economics from The Ohio State University.
Ernst Heinen, DVM, Ph.D.
Chief Development Officer
Ernst Heinen, DVM, Ph.D., has served as our Chief Development Officer since March 2014. In addition, he served as our Head of Drug Evaluation and Development from June 2012 until March 5, 2014. From 1990 to 2012, Dr. Heinen held positions of increasing responsibility at Bayer Animal Health, the animal health division of Bayer AG, where he ultimately served as Vice President of Research & Development and Veterinary Technical Services, Pets. Dr. Heinen currently serves on the Kansas State University Olathe Advisory Board and previously served on the boards of the Kansas City Area Development Council and the Center for Animal Health Innovation, and he is the author of dozens of scientific articles and presentations focused on the animal health industry. Dr. Heinen received a veterinary degree and a D.V.M. in veterinary microbiology from the Justus-Liebig-University of Giessen Veterinary School in Giessen, Germany, and is a certified specialist in veterinary microbiology.
John Ayres, J.D.
General Counsel & Secretary
John Ayres, J.D. is General Counsel and Secretary of Aratana Therapeutics with more than a decade of experience representing pharmaceutical, medical device, and technology companies. Before joining Aratana, he served as corporate and securities counsel for California-based Amgen Inc., the world’s largest independent biotechnology company. Prior to joining Amgen, he was an associate at Latham & Watkins LLP in Chicago, where he specialized in public company representation and corporate transactions. Mr. Ayres earned his Juris Doctorate degree from the University of Missouri. He also earned a B.A. degree in finance from Truman State University. He is a member of the Bar of the state of Missouri and the state of Illinois.
Jeff Jones, Ph.D.
Vice President of Business Development
Jeff Jones, Ph.D., is the Vice President of Business Development and joined Aratana from PharmAthene where he held positions in business development and most recently served as Chief Operating Officer. Prior to PharmAthene, Dr. Jones was a Principal at Emerging Technology Partners, LLC, a life sciences focused venture capital fund. Dr. Jones holds a Ph.D. in Cell and Molecular Biology from Baylor College of Medicine, an MBA from Cornell’s Johnson Graduate School of Management and a B.A. in Biology from the University of Virginia.
Vice President of Human Resources
As Vice President of Human Resources, Debra Walls, M.B.A., brings more than 20 years of experience from a wide variety of industries, including automotive, aerospace, technology and animal health. Before joining Aratana, Ms. Walls served as Director of Human Resources for Fishnet Security where she was a member of the executive team and lead a team of a dozen supporting the organization’s overall HR strategy. Prior, she worked for seven years at Wyeth’s Fort Dodge Animal Health and was responsible for the division’s compensation and benefits programs and also lead the transition of employees after the Pfizer acquisition. Ms. Walls holds her Masters of Business Administration from the Williams College of Business at Xavier University and a B.S. in organizational leadership from Purdue University.